Pfizer has announced the completion of a global (ex-China) licensing agreement with Chinese biopharma company 3SBio, acquiring exclusive rights to develop, manufacture, and commercialize SSGJ-707, a novel bispecific antibody targeting PD-1 and VEGF. Developed using 3SBio’s proprietary CLF2 platform, SSGJ-707 is currently in multiple clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors.

Positive interim Phase 2 results for SSGJ-707 as a monotherapy in advanced NSCLC were recently presented at the ASCO Annual Meeting, underscoring its potential. Pfizer intends to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas. The next phase of clinical development will span the U.S. and global trial sites, with a priority focus on launching Phase 3 trials for NSCLC and other solid tumors, beginning with patient enrollment in the U.S.

As part of the deal, 3SBio will receive an upfront payment of USD 1.25 billion, along with aUSD100 million equity investment from Pfizer. The agreement also includes an option for Pfizer to secure exclusive rights in China, for which it may pay up to USD150 million in option payments.

This partnership marks a major step in Pfizer’s oncology pipeline expansion and highlights growing global interest in bispecific antibody therapies targeting multiple cancer pathways.